Breaking News

Novozymes, Janssen In VELTIS Technology Pact

By Kristin Brooks | March 21, 2014

Will evaluate VELTIS technology for potential drug candidates

Novozymes Biopharma has entered a collaboration with Janssen Research & Development, LLC under which Janssen will evaluate Novozymes’s engineered albumin-based VELTIS technology for potential drug candidates. Novozymes' VELTIS technology represents a series of engineered human albumins that in combination with a drug candidate, offers the potential for control of the therapeutic half-life, which allows for reducing the dosing frequency of drugs from daily to every two weeks or monthly.
 
"We are delighted to be working with Janssen on this important collaboration," said Svend Licht, senior director, Novozymes Biopharma. "The VELTIS half-life extension technology can be linked to a broad range of drug candidates and the agreement is central in our continued strategy to demonstrate its potential to facilitate greater control across many therapeutic fields. The VELTIS platform is a transformative technology that offers real potential to revolutionize the delivery of treatments. Working with partners across a wide-range of medical conditions, we are continuing to highlight the benefits of the solution in improving the lives of patients."

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research